Method of spontaneous erythrocyte aggregation relief in newborn calves with anaemia

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves three intramuscular introduction of ferroglucin 75 mg (1 ml) every 5 days, three intramuscular introduction of phosprenyl by different syringes in different points simultaneously with an iron preparation, 0.12 ml/kg for the first injection, 0.10 ml/kg for the second injection, 0.08 ml/kg for the third injection, and the intramuscular injections of gamavit 0.018 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to prevent vascular complications in newborn calves with anaemia, to optimise microcirculation and tissue trophism, to hasten the growth, to improve a herd, to produce greater amount of meat production, to produce an expected healthy posterity from these animals.

1 ex

 

The invention relates to biology and veterinary medicine.

Analogues of the proposed method of correction of the spontaneous aggregation of erythrocytes (SAE) in newborn calves with anemia does not exist.

In the literature there is information on the application of anemia in calves feroglobin (Internal non-infectious diseases of farm animals./Edited Vmenyaemogo. M: Agropromizdat, 1991. - 576 S.).

As an effective stimulant of life growing organism in modern veterinary medicine applied fosprenil - drug-based phosphate polyprenols, obtained from the needles and gamavit - complex balanced means on the basis of the placenta, containing nukleinat sodium, set of amino acids, vitamins and salts (Deeva AV, Salakhova Z.A., Lobova et al. improve the safety and productivity of pigs when using fosrenol and amavita. Veterinary science. - 2006. No. 4. - S-15).

However, never before medical complex consisting of feroglobin, fosrenol and guavita, was not used in newborn calves with anemia to optimize their level SAE immediately after the end of treatment.

The aim of the invention is to increase the optimization level SAE newborn calves with anemia.

The essence of the proposed method is that the optimization level SAE newborn calves with anemia is assigned to errornuker 75 mg (1 ml) intramuscularly, three times with an interval of 5 days, fosprenil intramuscularly, three times in different syringes at different points simultaneously with the preparation of iron, for the first time of 0.12 ml/kg for the second time in a dose of 0.10 ml/kg, for the third time in a dose of 0.08 ml/kg and gamavit 0,018 ml/kg intramuscularly once a day for eight days, beginning with the first injection feroglobin.

The method allows to optimize the level SAE newborn calves with anemia immediately after treatment, translating SAE at a level close to that of healthy calves. When you follow the advice of the proposed method can be maintained in the subsequent level of fibrinogenesis in an optimal state, which will allow newborn calves with anemia significantly reduce the risk of thrombotic complications.

The inventive method is carried out as follows.

Erythrocyte aggregation is assessed by the degree of ability of erythrocytes to spontaneously aggregate (Pokrova O.A., Grineva MR, Ivanov K.S. Methodology and clinical significance of the study the rheological properties of blood. Bulletin of the Ivanovo medical Academy. - 2008. - So 13, No. 1-2. - S.89-98).

To assess the aggregation of erythrocytes blood from a vein taken in sodium citrate in the ratio of 9:1 and centrifuged 10 min at 3000 rpm./minutes In 96-well pad fill 2 holes 0.2 ml plasma of the subject. From the tube removed all the plasma and the layer of leukocytes. Aritri what you resuspended standard phosphate buffer in the ratio 1:4, followed by centrifugation for 10 min at 3000 rpm./min, that allows you to wash them from the remnants of the plasma when removing the supernatant. After this is taken as 0.02 ml of erythrocytes and resuspended first filled with autologous plasma-well 96-well Ouija boards, allowing you to get 10% hematocrit. Then from this hole, take a clean, dry pipette 0,02 ml content and placed in the second filled the hole that allows you to get 1% hematocrit. After that 1 grid in the camera Goryaeva fill obtained a suspension of red blood cells, incubated 3 min for the occurrence of spontaneous aggregation and shall count free erythrocytes (including 2 of the erythrocyte together) and units, starting with 3 cells, connected in the form of "monetary columns") in 2 large squares of the camera (lens × 40, eyepiece × 10). Considered the number of "coin of columns and the number of red blood cells, involved in them.

Based on these results, calculate the following indicators that assess SAE:

1) Average unit size (CPA):

CPA=sea/KA;

Sea - the sum of all cells in the units;

KA is the number of units;

2) the Index of aggregation (PA):

PA=(CPA·KA+CTU)/(KA+CTU),

CTU - free erythrocytes;

3) the Percentage of non-aggregated RBCs (PNA):

PNA=CSE·100/(CPA·KA+CSP).

Normative values for CPA are 4-5, PA 1,05-1,30, for the PNA 80,0-92,0%. The increase in CPA in the above 5, PA above 1.30 and lowering the PNA below 80,0% talks about increasing the SAE. In case of violation of at least one of these three indicators of sick animals must be treated according to the inventive method.

When establishing newborn calves with anemia strengthened SAE, they are assigned therapy according to the inventive method, feroglobin 75 mg (1 ml) intramuscularly three times with an interval of 5 days, fosprenil intramuscularly, three times in different syringes at different points simultaneously with the preparation of iron, for the first time of 0.12 ml/kg for the second time in a dose of 0.10 ml/kg, for the third time in a dose of 0.08 ml/kg and gamavit 0,018 ml/kg intramuscularly once a day for eight days, beginning with the first injection feroglobin.

Example. The newborn calf with anemia No. 52, the amount of hemoglobin was 81,5 g/l, erythrocytes was 4.02×1012/l, sideration of 1.3% when the level of iron in serum of 13.4 µmol/l increase in total iron-binding capacity of serum to 70.2 mmol/l elevated levels SAE (CPA=5,8, PA=1,76, PNA=53,9%).

The calf was assigned feroglobin 75 mg (1 ml) intramuscularly three times with an interval of 5 days, fosprenil intramuscularly, three times in different syringes at different points simultaneously with the preparation of iron, for the first time of 0.12 ml/kg for the second time in a dose of 0.10 ml/kg, for the third time in a dose of 0.08 ml/kg and gamavit 0,018 ml/kg intramuscularly once a day for eight days, beginning the Naya with the first injection feroglobin.

Calf were checked regularly during treatment and after it. After treatment, the calf is normalized red blood. Thus, the amount of hemoglobin had risen to 127,0 g/l, erythrocytes - to 4.95×1012/l, sideration to 8.8% increase in iron in the serum to 23.9 mmol/l and decreased total iron-binding capacity of serum to 35.3 μmol/l, SAE normalized (CPA=4,8, PA=1,15, PNA=82,5%).

The use of the proposed method optimization level SAE in biology and veterinary medicine will help to avoid vascular complications in newborn calves with anemia, optimize them microcirculation and trophism of tissues, accelerating the growth of animals, ozdorovyv herd that will allow you to get more high-quality meat products from these animals in the subsequent healthy offspring.

The method of normalization of the spontaneous aggregation of erythrocytes of newborn calves with anemia by applying feroglobin 75 mg (1 ml) intramuscularly three times with an interval of 5 days, fosrenol intramuscularly, three times in different syringes at different points simultaneously with the preparation of iron, for the first time of 0.12 ml/kg for the second time in a dose of 0.10 ml/kg, for the third time in a dose of 0.08 ml/kg and amavita 0,018 ml/kg intramuscularly once a day for eight days, beginning with the first injection feroglobin.



 

Same patents:

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves prescription of two intramuscular injection of ferroglucin 150 mg (2 ml) every 10 day, three intramuscular injections of phosprenyl in different syringes into different points, 0.12 ml/kg for the first time together with an iron agent, 0.10 ml/kg five days after the first injection of ferroglucin, 0.07 ml/kg for the third time together with the second injection of ferroglucin and intramuscular injections of gamavit 0.020 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to normalise spontaneous erythrocyte aggregation in suckling calves with anaemia, to provide higher additional weights, to reduce mortality and to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new imidazopyrazines of formula where Q1 and R1 have the values specified in the patent claim, and to their pharmaceutically acceptable salts showing IGF-1R enzyme inhibiting activity and applicable for treatment and/or prevention of various diseases and conditions which are sensitive to tyrosine kinase inhibition.

EFFECT: preparation of the compounds showing IGF-1R enzyme inhibiting activity.

27 cl, 294 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns application of at least one Lactobacillus plantarum strain specified from the group containing Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316 for preparing a composition improving adsorption iron or its ions by a mammal, preferentially a human. The composition contains a material carrier which is fermented by one or more strains specified from said group of lactic acid bacilli. To ensure better adsorption of iron or its ions, this composition is introduced in a mammal, preferentially a human. Said lactic acid bacilli are applied for preparing a pharmaceutical composition for treating anaemia.

EFFECT: invention provides better adsorption of iron or its ions, improves the general health and individual health due to better body adsorption of iron.

17 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: dispersing tablets contain as an active ingredient, deferasirox, 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazole-1-yl]benzoic acid or its pharmaceutically acceptable salt in amount 42 to 65 wt % on total mass basis, and a pharmaceutically acceptable excipient applicable for preparation of tablets. There is also described a method for preparing dispersing tablets by wet granulation technique.

EFFECT: dispersing tablets of deferasirox have disintegration time 5 minutes or less.

13 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in contraction of anaemia accompanying the chemoradiation therapy. That is ensured by blood exfusion in amount 8-10% of the circulating blood volume, and the removed blood volume is replaced with crystalloids in the ratio 1:1. From the exfused blood, erythrocyte concentrate is recovered whereto Essentsiale N solution 5 ml is added; the prepared mixture is placed in a thermostat at temperature 37°C for 10 minutes. Then 100 ml of a physiologic saline is added to said mixture that is rocked. The prepared solution is introduced to the patient within 20 minutes with a simultaneous UV blood irradiation. Exfusion and extracorporal blood processing combined with UV irradiation are performed every second day, 2-3 sessions for the therapeutic course.

EFFECT: method allows reducing time for normalisation of the blood erythrocyte level and haemoglobin with maintaining the time intervals for chemoradiation therapy courses and without reducing the dosage of chemopreparations and radiation tumour load.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention is related to chemical-pharmaceutical industry, namely to development of agent for recovery of haematogenic function in case of toxic haemolytic anaemia and method of its production on the basis of stinging nettle. Agent for recovery of haematogenic function in case of toxic haemolytic anaemia contains powder of stinging nettle leaves and stems, which are nanodispersed down to size of 50-90 nm. Method of agent production includes drying of stinging nettle leaves and stems down to residual moisture of 4-6 wt %, grinding down to size of 50-90 nm in ball crushers of planetary, vibration, vibrocentrifugal, roller types, which provide for acceleration of grinding bodies, for instance balls, up to 400 m/s2 in the medium of argon or nitrogen.

EFFECT: agent produced with this method does not have toxic effect, has higher content of chlorophylls.

2 cl, 1 tbl, 10 ex

FIELD: biotechnology.

SUBSTANCE: invention concerns biotechnology and conjugates of hydroxyalkyl starch and protein of factor (G-CSF) stimulating granulocyte colonies. The conjugates are formed by covalent link between hydroxyethyl starch or its derivative with molecular weight within 2 to 200 kD and protein.

EFFECT: methods of conjugate obtainment and application.

26 cl, 7 ex, 2 tbl, 21 dwg

FIELD: medicine .

SUBSTANCE: invention refers to medicine and namely to pharmacology and deals with remedies influencing free-radical processes, hemorheology, thrombocyte aggregation and intravascular thrombosis. It has been proposed to use (3,5-dimethyl-4- hydroxy)benzyl thiododecane which is known for its antioxidant activity as antiaggregant remedy decreasing blood hyperviscosity, and antithrombogenic remedy.

EFFECT: there has been shown the stated effectiveness of the remedy by means of blood hyperviscosity pattern and increase of blood flow under conditions of its complete stop when there are no thrombs in arteria the next day.

4 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine, namely to haematology and can be used for treatment of hematopoietic erythroid lineage depression in cytostatic myelosuppression. It is ensured by introduction of Cyproheptadine in a dose 30 mg/kg, 30 minutes prior to introduction of a cytostatic agent. The next days, cytostatic action is followed with introduction of Recormone dosed 10 UN/a mouse once a day within 5 days.

EFFECT: method provides effect potentiation and reduction of adverse reaction of Recormone, ensuring normalised content of erythroid cells in peripheral blood.

1 ex, 5 tbl

FIELD: pharmacology.

SUBSTANCE: claimed is preparation for pharmacological correction of erythropoiesis disturbances, developing under cytostatic influence, - cyproheptadine. Said antiserotin preparation was introduced 30 minutes before cytostatic 5-fluoruracyl. This resulted in formation of additional areas of erytyhroid and mixed hematopoiesis.

EFFECT: cyproheptadine increased number of eryth-rocariocytes in bone marrow and reticulocytes in peripheral blood.

5 tbl, 1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves prescription of two intramuscular injection of ferroglucin 150 mg (2 ml) every 10 day, three intramuscular injections of phosprenyl in different syringes into different points, 0.12 ml/kg for the first time together with an iron agent, 0.10 ml/kg five days after the first injection of ferroglucin, 0.07 ml/kg for the third time together with the second injection of ferroglucin and intramuscular injections of gamavit 0.020 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to normalise spontaneous erythrocyte aggregation in suckling calves with anaemia, to provide higher additional weights, to reduce mortality and to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to pharmacology. Medication for brain cell protection contains dominant protein extract from placenta tissue, obtained by chromatographic separation of protein fraction of 8-10 components with total molecular weight from 15 to 200 kDa, 70-80% of fraction consisting of protein with molecular weight about 70 kDa. In order to obtain said medication powdered placenta is extracted by means of alkalescent buffer in presence of inhibitors of proteolytic protein cleavage and centrifuged. Centrifugate is passed through chromatographic column with anion-exchange carriers balanced by means of the same buffer, column is washed from unbound material, proteins are eluted with neutral salt solution. Collected material is diluted with water bringing pH to subacid value and diluted substrate is successively passed through column with anion-exchange carrier and column with cation-exchange carrier, balanced with buffer solutions to pH about 6.0. Final product is obtained after sterilisation.

EFFECT: method application allows to obtain efficient medication of high purity, normalising nervous system functions.

3 cl, 1 tbl, 4 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves three intramuscular introduction of ferroglucin by 75 mg (1 ml) every 6 days, three intramuscular introduction of phosprenyl by different syringes in different points simultaneously with an iron preparation, 0.10 ml/kg for the first injection, 0.08 ml/kg for the second injection, 0.07 ml/kg for the third injection, and the intramuscular injections of gamavit 0.017 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows normalising the level of spontaneous thrombocyte aggregation, helps to avoid vascular complications in newborn piglets with anaemia, to optimise microcirculation and tissue tropism, to accelerate growth of animals, to improve a herd, to provide higher quality and amount of produced meat, to produce a healthy posterity.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves the introduction of 1% novocaine, denatured emulsified placenta, nettle tincture and Endometromag T. 10 minutes after foetus birth, 1% novocaine is introduced in dosage 100 ml with puncture procaine block assistance, and for the 6th day after calving, novocaine is introduced once again in the same dose; denatured emulsified placenta is introduced suncutaneously in dosage 20 ml immediately after calving and 72 hours after calving; nettle tincture prepared by covering nettle with boiling water in the ratio 1:20 is introduced in dosage 5 l for the first days and for the next 3 days running, and Endometramag T is administered intrauterinally on the first days after calving in dosage 100 ml.

EFFECT: method is effective in the prevention of postnatal subinvolution of uterus in cows, allows accelerating lochia elimination from uterus to be prepared for a new pregnancy.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Method of obtaining placental medication on the basis of cows' placenta is characterised by the following: in period of evisceration of incalvers at slaughterhouse, pregnant uterus is removed in the first half of pregnancy (4-5 months), non-separated caruncles and cotyledons are collected from baby's and maternal placenta by cutting cotyledons with curved sterile scissors from baby's placenta, which is made through longitudinal cut in serous-muscular-mucous layer of pregnant uterine horn, puncturing with a needle chorionically amniotic membrane by vacuuming amniotic fluid is collected from amniotic bubble; cut off cotyledond are crushed with caruncles by cutting, after that in mechanical homogeniser, amniotic fluid, previously collected from the same uterus, is added in amount 10:1 of homogenous mass, slowly mixed and settled, after that centrifuged at 10 thousand rev/min for 10 minutes, conservation is performed, supernatant part is poured into vials and sealed.

EFFECT: invention ensures increase of preparation efficiency.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Method of obtaining biologically active tissue preparation based on cows' placenta includes filtration, crushing, homogenisation, centrifugation, pregnant uterus being removed in the first half of pregnancy (4-5 months) in period of evisceration of incalvers at slaughterhouse, longitudinal cut of serous-muscular-mucous layer of pregnant uterine horn is performed, cotyledons are collected by removing them from caruncles, preserving integrity of villi, cutting cotyledons with curved sterile scissors from tissue of baby placenta, puncturing with a needle chorionically amniotic membrane by vacuuming amniotic fluid is collected from amniotic bubble, cut cotyledons are crushed by cutting, and after that in homogeniser, earlier collected from the same uterus amniotic fluid is added in amount 10:1 of homogeneous mass, mixed slowly and settled, after that centrifuged at 10 thousand rev/min for 10 minutes, conservation is performed, supernatant part is poured into vials and sealed.

EFFECT: invention ensures increase of preparation efficiency.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine, namely to therapy of radiation sickness of laboratory animals, and deals with restoration of myeloid tissue after exposure to ionising irradiation. For this purpose one hour after irradiation intravenous allogenic transplantation of multipotent mesenchymal stromal cells, separated from placenta, in quantity of 6×106 cells/kg is carried out.

EFFECT: such regimen of transplant introduction insures efficient restoration of myeloid tissue of old laboratory animals and allows to extend arsenal of means for anti-radiation therapy.

5 tbl

FIELD: veterinary science.

SUBSTANCE: invention relates to veterinary medicine and is to be utilised for prophylactics and treatment of cow reproductive malfunctions. The method envisages cow placenta preparation. The prepared cow placenta is chilled. Then the placenta having been chilled is homogenised and exposed to microwave radiation at a frequency of 2450±50 MHz, with the raw material heated to a temperature of no more than +60°C. Then the resultant liquid is mixed with distilled water at a ratio of 1:4 and boiled during 10 minutes. Then the resultant liquid is chilled, centrifuged and filtered. Then the resultant liquid is mixed with Fraction 2 Dorogov antiseptic stimulant, bringing the concentration of Fraction 2 Dorogov antiseptic stimulant to 4% of the total liquid volume; after that one adds a 20% alcoholic solution of thymol in an amount of 0.1% of the total liquid volume. Then the resultant preparation is autoclaved.

EFFECT: proposed invention enables improvement of cow impregnation capacity after initial insemination.

1 tbl, 2 ex

FIELD: pharmacology.

SUBSTANCE: invention refers to medicine, veterinary science and agriculture. There is presented exogenous modulator of metabolic and energy interchange processes between a cell and environment representing a polypeptide metabolic process modulator of molecular weight 15 to 10 KDa made of human placenta by chemical modification of placental biobased products with reactions of chlorination, oxidation, hydrolysis, and containing covalently bound chlorine atoms with nitrogen atoms of peptide bond in amount 0.5 to 40% of weight of an end product. There is also offered method for making said modulator.

EFFECT: correction and regulation of metabolic processes to ensure maximum viability of human body, animals and plants.

7 cl, 8 tbl, 10 ex

FIELD: veterinary.

SUBSTANCE: method consists in introducing of mesenchymal stem cells of umbilical cord or placenta, taken after normal childbirth. Endolymphatic introduction of cells is performed by injections of 1-2 ml of physiological solution, which contains 0.075-0.20×106 cells/kg of weight along spine or leg in single-step1-2 times per year.

EFFECT: method allows to improve animal's condition, increasing of its activity, normalises metabolism.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves prescription of two intramuscular injection of ferroglucin 150 mg (2 ml) every 10 day, three intramuscular injections of phosprenyl in different syringes into different points, 0.12 ml/kg for the first time together with an iron agent, 0.10 ml/kg five days after the first injection of ferroglucin, 0.07 ml/kg for the third time together with the second injection of ferroglucin and intramuscular injections of gamavit 0.020 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to normalise spontaneous erythrocyte aggregation in suckling calves with anaemia, to provide higher additional weights, to reduce mortality and to produce an expected healthy posterity from these animals.

1 ex

Up!